Organogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Up 29.1% in December

Organogenesis Holdings Inc. (NASDAQ:ORGO) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 11,000,000 shares, a growth of 29.1% from the November 30th total of 8,520,000 shares. Approximately 16.3% of the shares of the stock are sold short. Based on an average trading volume of 690,900 shares, the days-to-cover ratio is presently 15.9 days.

Organogenesis Stock Down 2.7 %

ORGO opened at $3.19 on Friday. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The business’s fifty day simple moving average is $3.46 and its 200 day simple moving average is $3.03. Organogenesis has a 52 week low of $2.16 and a 52 week high of $4.70. The stock has a market cap of $401.07 million, a PE ratio of -53.17 and a beta of 1.73.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.11. The firm had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period in the prior year, the company earned $0.02 EPS. As a group, research analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Gary S. Gillheeney sold 55,615 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $3.36, for a total transaction of $186,866.40. Following the sale, the chief executive officer now owns 3,044,779 shares in the company, valued at approximately $10,230,457.44. This trade represents a 1.79 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 278,116 shares of company stock worth $991,190 in the last ninety days. 36.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Organogenesis

A number of institutional investors have recently made changes to their positions in ORGO. Captrust Financial Advisors bought a new stake in shares of Organogenesis in the 3rd quarter valued at about $36,000. Delap Wealth Advisory LLC bought a new stake in Organogenesis in the second quarter valued at approximately $40,000. Intech Investment Management LLC purchased a new stake in shares of Organogenesis during the third quarter valued at approximately $43,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Organogenesis by 4,989.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after purchasing an additional 15,369 shares during the last quarter. Finally, Pallas Capital Advisors LLC increased its stake in shares of Organogenesis by 70.8% in the third quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock worth $63,000 after buying an additional 9,048 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.